about
Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.Epigenetic activation of SOX11 in lymphoid neoplasms by histone modifications.Methylation of the nonhomologous end joining repair pathway genes does not explain the increase of translocations with aging.S-Adenosylmethionine increases circulating very-low density lipoprotein clearance in non-alcoholic fatty liver disease.Genetic variants in miRNA processing genes and pre-miRNAs are associated with the risk of chronic lymphocytic leukemia.Confirmation of involvement of new variants at CDKN2A/B in pediatric acute lymphoblastic leukemia susceptibility in the Spanish populationDetection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia.A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia.Pharmacogenetics of childhood acute lymphoblastic leukemia.Potential relationship between single nucleotide polymorphisms used in forensic genetics and diseases or other traits in European population.A systematic review and meta-analysis of MDM2 polymorphisms in osteosarcoma susceptibility.MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy.Alpha2C-adrenoceptor Del322-325 polymorphism and risk of psychiatric disorders: significant association with opiate abuse and dependence.Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.Research commentary regarding Savage et al. entitled "Genome-wide association study identifies two susceptibility loci for osteosarcoma".Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia.Genetic susceptibility in childhood acute lymphoblastic leukemia.PNPLA3 rs738409 and Hepatotoxicity in Children With B-cell Acute Lymphoblastic Leukemia: A Validation Study in a Spanish Cohort.The miR-1206 microRNA variant is associated with methotrexate-induced oral mucositis in pediatric acute lymphoblastic leukemia.MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia.Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia.Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population.Erratum to: Potential relationship between single nucleotide polymorphisms used in forensic genetics and diseases or other traits in European population.Polymorphisms in miRNA processing genes and their role in osteosarcoma risk.Chromosome instability in lymphocytes of children with coeliac disease.Letter regarding Wang et al. entitled "Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systematic review and meta-analysis".Noncoding RNA-related polymorphisms in pediatric acute lymphoblastic leukemia susceptibility.Intron 3 of the ARID5B gene: a hot spot for acute lymphoblastic leukemia susceptibility.Re: novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations.Role of miRNAs in treatment response and toxicity of childhood acute lymphoblastic leukemia.Variants in the 14q32 miRNA cluster are associated with osteosarcoma risk in the Spanish populationPharmacoepigenetics in childhood acute lymphoblastic leukemia: involvement of miRNA polymorphisms in hepatotoxicityNon-leukemic pediatric mixed phenotype acute leukemia/lymphoma: Genomic characterization and clinical outcome in a prospective trial for pediatric lymphoblastic lymphomaCell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic reviewInvolvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment
P50
Q27312570-5B658047-6479-4575-B207-852065A9D383Q33954847-D66424D1-605B-4BF5-B7F6-82B1FFF564ACQ34517258-A0C8F83E-EF87-4F0D-BCE3-E195735657AEQ35108120-9FDF5C74-CA1C-4C71-B815-DBD46CCE72E3Q35582415-8E5B904D-021A-4BB8-98E3-B1345ACCBCB5Q36365728-1722BBB0-30EC-47CF-ABDC-3EEBBCD1C056Q36799831-5A73AFFB-0F1F-4B53-BC1F-DD79D629C473Q38054428-7FACE570-D3CC-49B5-8F78-A2858C4C5EA2Q38243175-CB8B0B03-4E7E-4307-B286-797E6ED796F9Q38375055-0A303860-708E-4D92-AE8F-A292F4B105F5Q38839781-902B3FDD-B896-4AB4-80C7-BEA3D85A401CQ39230513-F58CDA8B-BF00-4140-A4FB-E89D04486536Q39894765-3FA2542F-BAAB-46BB-B1D5-0106DF7E93DFQ42746762-F97F5E59-E9A8-4A90-8A77-936F259F996BQ46853649-282095F5-802B-4F73-912C-5EC86D04AF45Q47177557-26F486FF-566E-4A1C-A1B2-EB1BF96E121CQ47193441-AAB36714-3599-45AC-8A3F-52FAF8D20B14Q47201317-097BE2A7-F836-493F-BA23-14CDFF7B0C86Q47206896-63A284F7-5D95-4D62-842B-887F4E214301Q47267570-DD9DBCB2-7E22-4DEC-BD41-35466F6FA3D8Q47310338-D6A825AA-AE0E-40F1-BB03-97BA8AF82E0AQ47358258-E27B73CE-F9FF-4ACB-A380-876454214042Q47390783-93BAFCF4-14D5-4EA1-BB43-96E148C8319EQ47438993-5559F1CE-4FDF-42BF-9FE8-7292CD6A6D39Q47589856-4BDB34FA-87BD-4293-A0C6-2D5A3787F2BCQ47657846-04AB1C1C-EB09-42E1-9523-07C6F5E32277Q47663573-7EBC9283-9991-42EC-AC65-4CA992A036BCQ47722451-80CE9F0B-B6EF-44AF-81C7-F23AA1919745Q47722492-5C38BA01-6352-4081-A959-56DEB8345232Q52690565-FDEEC666-DA5C-4E3A-9AFB-79A7C7AABFA4Q58603625-F20EC85F-8E59-4A01-A999-CC1AE4BE1BF4Q88143296-EA674E20-8D95-4174-B33F-1F11A4666AA9Q90713946-9BB57C78-D5B5-4945-A3A0-96DABBFE2CD6Q92190722-72D1D4EC-40C3-41F7-A758-F81E86470B3BQ93385655-7FC50542-29EE-455A-A887-D4719C2EB6EA
P50
description
investigador
@es
researcher
@en
name
Idoia Martin-Guerrero
@en
type
label
Idoia Martin-Guerrero
@en
prefLabel
Idoia Martin-Guerrero
@en
P31
P496
0000-0002-0098-1908